InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,222.68
(
0.16%
)
US TECH 100
17,718.00
(
0.20%
)
Dow Jones
39,512.84
(
0.32%
)
Brent Oil
82.86
(
0.57%
)
Bitcoin
62,677.45
(
2.00%
)
Post# of 20775
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

john1045

Send PM Follow Ignore
Followers 36
Posts 2689
Boards Moderated 0
Alias Born 06/09/2011

john1045

Re: Shaka_Zulu post# 15387

Sunday, 07/20/2014 7:42:25 AM

Sunday, July 20, 2014 7:42:25 AM

Post# of 20775
Shaka....I agree with you on Maza being from Goldman Sachs and realizes patent portfolio alone has multi-billion dollar potential in future revenues in a wide array of diseases in which there are currently no approved products in the market.

Pfizer must see the patent portfolio and easily implement multiple trial in many diverse diseases plus with Ponezumab reaching primary endpoint in October/November 2014 they are probably seeing results already in this trial.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up